CME Credits: 0.25
Diagnosis and staging of MASLD/MASH
GlobalProfessor Sven Francque describes the diagnostic pathway for patients with MASLD and discusses strategies for disease stratification.
Encountering and managing MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease, or MASLD, previously known as non-alcoholic fatty liver disease, or NAFLD, is estimated to affect a quarter of the general population and over 50% of those who are obese or have diabetes. MASLD denotes a spectrum of liver disease from steatosis alone, to steatohepatitis (known as MASH) and cirrhosis.
This animation series, developed and narrated by multidisciplinary experts in the field, discusses diagnosis and staging of MASLD, including non-invasive testing strategies, management and monitoring of the disease, and organization of care across the multidisciplinary team.
Pre-Activity Information
- Target Audience
- Learning Objectives
- Faculty & Disclosures
- Funding Information
- Release Date
- Accreditation
Primary care providers including general practitioners, nurses, and pharmacists.
Specialists including hepatologists, endocrinologists, and gastroenterologists.
This educational activity is intended for healthcare professionals outside of the UK.
After completing this educational activity, learners will be able to:
- Identify the routine and symptom-directed tests that indicate MASLD at various disease stages
- Stratify patient risk using non-invasive tools
- Organize the clinical treatment route for patients based on their individual requirements, taking into account the most up-to-date guidelines and expert recommendations
- Organize collaborative multidisciplinary efforts based on personalized patient needs
Local Expert for Global: Professor Sven Francque
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Consulting Fees | Abbvie, Actelion, Aelin Therapeutics, Allergan, Astellas, Astra Zeneca, Bayer, Boehringer Ingleheim, Bristol Myers Squibb, CSL Behring, Coherus, Echosens, Eisai, Enyo Pharma, Galapagos, Galmed Pharmaceuticals, Genentech, Genfit, Gilead Sciences, Intercept, Inventiva, Janssen, Julius Clinical, Madrigal Pharmaceuticals, MedImmune, Merck Sharp & Dohme, NGM Bio, Novartis, Novo Nordisk, Promethera Biosciences, Roche |
| Lectures/Presentations | Abbvie, Allergan, Bayer, Eisai, Genfitm Gilead Sciences, Janssen Cilag, Intercept, Inventiva, Merck Sharp & Dohme, Novo Nordisk, Promethera Biosciences |
| Grants/Contracts | Astellas, Dr Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Inventiva, Janssen, Merck Sharp & Dohme, NGM Bio, Pfizer, Roche |
Local Expert for Global: Dr. Juan Mendive
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisor | Novo Nordisk, Reckitt |
Local Expert for Global: Professor Herbert Tilg
Professor Herbert Tilg has no financial relationships to disclose
Staff Disclosures
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use:
Pioglitazone, vitamin E and resmetirom are discussed in the context of MASH. Additionally, farnesoid X receptor agonists, FGFR19 analogs, GLP-1 receptor agonists, glucagon agonists, GIP receptor agonists, SGLT2 inhibitors, and thyroid hormone receptor beta agonists are also discussed as classes of therapy in context of MASH.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Novo Nordisk A/S had no influence on the content of this educational activity.
Diagnosis and staging of MASLD/MASH
This module was accredited on April 18, 2024 and will expire on April 18, 2025.
Managing and monitoring MASLD/MASHThis module was accredited on April 22, 2024 and will expire on April 22, 2025.
Multidisciplinary care and referrals in MASLD/MASHThis module was accredited on April 22, 2024 and will expire on April 22, 2025.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™ Physicians should claim credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Video
CME Credits: 0.25
Managing and monitoring MASLD/MASH
GlobalDr. Juan Mendive discusses the current and future management of MASLD, highlighting the need for a holistic approach including consideration of comorbidities and regular monitoring.
CME Credits: 0.25
Multidisciplinary care and referrals in MASLD/MASH
GlobalProfessor Herbert Tilg and Dr. Juan Mendive review the organization and responsibilities of the multidisciplinary team throughout the MASLD patient journey.